SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for Treatment of Post Surgical Pain in the Home Setting

SteadyMed Ltd.

today announced positive results from the completion of a Phase 1 pharmacokinetic (PK), tolerability and safety, proof of concept clinical study with ketorolac, a non-steroidal anti-inflammatory drug (NSAID) used for the short-term treatment of moderately severe acute pain post-surgery. The results from this study were favorable and support further development of the Company's SMT-201 At Home Patient Analgesia (AHPA) program. SMT-201 is a combination of SteadyMed's PatchPump® technology and ketorolac, that is intended to provide patients with up to five days of post-surgical pain relief at the opioid level in the home setting from a non-opioid therapy. The current standard of care for ketorolac therapy must be initiated in the hospital or surgical center with either intravenous (IV) infusion or multiple intra-muscular (IM) injections. The study data demonstrated that a continuous subcutaneous infusion of ketorolac over 24 hours resulted in equivalent bioavailability compared to IM injections administered at six-hour intervals over 24 hours. In addition, this continuous 24-hour subcutaneous infusion avoided the peaks and troughs in